Subscribe

AMCP News

Dr Klink and colleagues collected data on patient characteristics and healthcare resource use for 104 patients receiving an anti–TNF-alpha and 34 patients receiving abatacept who met criteria for eRPRA classification before receiving their first treatment with a bDMARD.

“Managing patients with PsA disease requires a greater understanding of how joints and skin respond differently to therapy. Control of both joint and skin symptoms are important for overall disease management of these patients,” Dr Muram and colleagues stated.


Results 1 - 2 of 2
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology